NCT06874595 Psychobiological Responses Following Exercise and Brain Stimulation
| NCT ID | NCT06874595 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Virginia Commonwealth University |
| Condition | Psychological |
| Study Type | INTERVENTIONAL |
| Enrollment | 29 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 29 participants in total. It began in 2025-03-19 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anxiety disorders are the most common mental health diagnosis in the US; 19.1% of U.S. adults (23.4% for females and 14.3% for males). In addition, the Global Burden of Disease study (2010) found that anxiety disorders were the sixth leading cause of disability (years of life lived with disability). These debilitating disorders are characterized by excessive worry and fear about everyday situations, and physical symptoms including restlessness, being easily fatigued, difficulty concentrating, irritability, muscle tension, or sleep disturbance. Furthermore, anxiety is linked to other mental disorders including depression and substance abuse; is associated with cardiovascular disease risk factors and a higher rate of cardiovascular disease; and is related to premature mortality. These data have led to the investigation of a breadth of plausible treatments for anxiety, including medications and psychotherapy. However, likely due to the breadth of complex mechanisms involved in the pathophysiology of anxiety disorders and the unfavorable side effects of various medications, a considerable number of individuals do not have a satisfactory response to these treatments. This has led investigators to examine plausible novel interventions to alleviate anxiety and its symptoms.
Eligibility Criteria
Inclusion Criteria: * Healthy adults * aged 18 to 50 * consent and complete a Physical Activity Readiness Questionnaire (PAR-Q) * be free from any neurological or psychiatric disorder * not be taking any medication that could affect the central nervous system * not have any contraindication for HD-tDCS (i.e. not having metal implanted in the head, pacemaker, medical bumps, seizures, lesions on the scalp or head ) or for bioelectrical impedance (i.e., electronic medical implant, such as a pacemaker or implantable cardioverter defibrillator, and limb amputation) * not be regular users of tobacco products (cigarettes, cigars, chewing tobacco) * not consume an average of more than ten alcoholic beverages per week Exclusion Criteria: * Individuals who do not meet the PAR-Q screening criteria for participation in moderate physical activity will be excluded from participating in this study * women who are pregnant will be exclude from this study
Contact & Investigator
Edmund Acevedo
PRINCIPAL INVESTIGATOR
Virginia Commonwealth University
Frequently Asked Questions
Who can join the NCT06874595 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Psychological. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06874595 currently recruiting?
Yes, NCT06874595 is actively recruiting participants. Contact the research team at eoacevedo@vcu.edu for enrollment information.
Where is the NCT06874595 trial being conducted?
This trial is being conducted at Richmond, United States.
Who is sponsoring the NCT06874595 clinical trial?
NCT06874595 is sponsored by Virginia Commonwealth University. The principal investigator is Edmund Acevedo at Virginia Commonwealth University. The trial plans to enroll 29 participants.